Biora submits updated IND application to FDA for BT-600 Oct. 30, 2023 5:37 PM ET Biora Therapeutics, Inc. (BIOR) By: Val Brickates Kennedy, SA News Editor FDA Iryna Drozd Biora Therapeutics (NASDAQ:BIOR) said it has submitted an updated Investigational New Drug application for its product candidate BT-600 to the FDA. The company said the application was submitted to support its first human clinical study of BT-600 in the treatment of moderate-to-severe ulcerative colitis. The product is a combination of its NaviCap ingestible drug delivery device and a proprietary liquid formulation of the drug tofacitinib. Biora said that it expects to remain on track with its Phase 1 clinical trial timeline.